Morbid liver manifestations are intrinsically bound to metabolic syndrome and nutrient intake based on a machine-learning cluster analysis
Copyright © 2022 Micó, San-Cristobal, Martín, Martínez-González, Salas-Salvadó, Corella, Fitó, Alonso-Gómez, Wärnberg, Vioque, Romaguera, López-Miranda, Estruch, Tinahones, Lapetra, Serra-Majem, Bueno-Cavanillas, Tur, Martín Sánchez, Pintó, Delgado-Rodríguez, Matía, Vidal, Vázquez, García-Arellano, Pertusa-Martinez, Chaplin, Garcia-Rios, Muñoz Bravo, Schröder, Babio, Sorli, Gonzalez, Martinez-Urbistondo, Toledo, Bullón, Ruiz-Canela, Portillo, Macías-González, Perez-Diaz-del-Campo, García-Gavilán, Daimiel and Martínez..
Metabolic syndrome (MetS) is one of the most important medical problems around the world. Identification of patient´s singular characteristic could help to reduce the clinical impact and facilitate individualized management. This study aimed to categorize MetS patients using phenotypical and clinical variables habitually collected during health check-ups of individuals considered to have high cardiovascular risk. The selected markers to categorize MetS participants included anthropometric variables as well as clinical data, biochemical parameters and prescribed pharmacological treatment. An exploratory factor analysis was carried out with a subsequent hierarchical cluster analysis using the z-scores from factor analysis. The first step identified three different factors. The first was determined by hypercholesterolemia and associated treatments, the second factor exhibited glycemic disorders and accompanying treatments and the third factor was characterized by hepatic enzymes. Subsequently four clusters of patients were identified, where cluster 1 was characterized by glucose disorders and treatments, cluster 2 presented mild MetS, cluster 3 presented exacerbated levels of hepatic enzymes and cluster 4 highlighted cholesterol and its associated treatments Interestingly, the liver status related cluster was characterized by higher protein consumption and cluster 4 with low polyunsaturated fatty acid intake. This research emphasized the potential clinical relevance of hepatic impairments in addition to MetS traditional characterization for precision and personalized management of MetS patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in endocrinology - 13(2022) vom: 15., Seite 936956 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.09.2022 Date Revised 28.09.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fendo.2022.936956 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34663945X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34663945X | ||
| 003 | DE-627 | ||
| 005 | 20231226031932.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fendo.2022.936956 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM34663945X | ||
| 035 | |a (NLM)36147576 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Micó, Víctor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Morbid liver manifestations are intrinsically bound to metabolic syndrome and nutrient intake based on a machine-learning cluster analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.09.2022 | ||
| 500 | |a Date Revised 28.09.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Micó, San-Cristobal, Martín, Martínez-González, Salas-Salvadó, Corella, Fitó, Alonso-Gómez, Wärnberg, Vioque, Romaguera, López-Miranda, Estruch, Tinahones, Lapetra, Serra-Majem, Bueno-Cavanillas, Tur, Martín Sánchez, Pintó, Delgado-Rodríguez, Matía, Vidal, Vázquez, García-Arellano, Pertusa-Martinez, Chaplin, Garcia-Rios, Muñoz Bravo, Schröder, Babio, Sorli, Gonzalez, Martinez-Urbistondo, Toledo, Bullón, Ruiz-Canela, Portillo, Macías-González, Perez-Diaz-del-Campo, García-Gavilán, Daimiel and Martínez. | ||
| 520 | |a Metabolic syndrome (MetS) is one of the most important medical problems around the world. Identification of patient´s singular characteristic could help to reduce the clinical impact and facilitate individualized management. This study aimed to categorize MetS patients using phenotypical and clinical variables habitually collected during health check-ups of individuals considered to have high cardiovascular risk. The selected markers to categorize MetS participants included anthropometric variables as well as clinical data, biochemical parameters and prescribed pharmacological treatment. An exploratory factor analysis was carried out with a subsequent hierarchical cluster analysis using the z-scores from factor analysis. The first step identified three different factors. The first was determined by hypercholesterolemia and associated treatments, the second factor exhibited glycemic disorders and accompanying treatments and the third factor was characterized by hepatic enzymes. Subsequently four clusters of patients were identified, where cluster 1 was characterized by glucose disorders and treatments, cluster 2 presented mild MetS, cluster 3 presented exacerbated levels of hepatic enzymes and cluster 4 highlighted cholesterol and its associated treatments Interestingly, the liver status related cluster was characterized by higher protein consumption and cluster 4 with low polyunsaturated fatty acid intake. This research emphasized the potential clinical relevance of hepatic impairments in addition to MetS traditional characterization for precision and personalized management of MetS patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a cluster | |
| 650 | 4 | |a dyslipidemia | |
| 650 | 4 | |a glucose disorders | |
| 650 | 4 | |a hepatic enzymes | |
| 650 | 4 | |a metabolic syndrome | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Dietary Proteins |2 NLM | |
| 650 | 7 | |a Fatty Acids, Unsaturated |2 NLM | |
| 650 | 7 | |a Cholesterol |2 NLM | |
| 650 | 7 | |a 97C5T2UQ7J |2 NLM | |
| 700 | 1 | |a San-Cristobal, Rodrigo |e verfasserin |4 aut | |
| 700 | 1 | |a Martín, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-González, Miguel Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Salas-Salvadó, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Corella, Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Fitó, Montserrat |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso-Gómez, Ángel M |e verfasserin |4 aut | |
| 700 | 1 | |a Wärnberg, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Vioque, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Romaguera, Dora |e verfasserin |4 aut | |
| 700 | 1 | |a López-Miranda, José |e verfasserin |4 aut | |
| 700 | 1 | |a Estruch, Ramon |e verfasserin |4 aut | |
| 700 | 1 | |a Tinahones, Francisco J |e verfasserin |4 aut | |
| 700 | 1 | |a Lapetra, José |e verfasserin |4 aut | |
| 700 | 1 | |a Serra-Majem, J Luís |e verfasserin |4 aut | |
| 700 | 1 | |a Bueno-Cavanillas, Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Tur, Josep A |e verfasserin |4 aut | |
| 700 | 1 | |a Martín Sánchez, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Pintó, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Delgado-Rodríguez, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Matía-Martín, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Vidal, Josep |e verfasserin |4 aut | |
| 700 | 1 | |a Vázquez, Clotilde |e verfasserin |4 aut | |
| 700 | 1 | |a García-Arellano, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Pertusa-Martinez, Salvador |e verfasserin |4 aut | |
| 700 | 1 | |a Chaplin, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Rios, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz Bravo, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Schröder, Helmut |e verfasserin |4 aut | |
| 700 | 1 | |a Babio, Nancy |e verfasserin |4 aut | |
| 700 | 1 | |a Sorli, Jose V |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez, Jose I |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Urbistondo, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Toledo, Estefania |e verfasserin |4 aut | |
| 700 | 1 | |a Bullón, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Canela, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Portillo, María Puy- |e verfasserin |4 aut | |
| 700 | 1 | |a Macías-González, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Perez-Diaz-Del-Campo, Nuria |e verfasserin |4 aut | |
| 700 | 1 | |a García-Gavilán, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Daimiel, Lidia |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, J Alfredo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in endocrinology |d 2010 |g 13(2022) vom: 15., Seite 936956 |w (DE-627)NLM208813357 |x 1664-2392 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:15 |g pages:936956 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fendo.2022.936956 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 15 |h 936956 | ||